Research Article
The Choice of Local Treatment Modalities for Patients with Brain Metastases from Digestive Cancers
Table 4
Baseline characteristics of patients receiving single therapy and patients receiving combination therapy.
| Characteristics | Before PSM | After PSM | Single therapy N = 134 | Combination therapy N = 37 | value | Single therapy N = 31 | Combination therapy N = 31 | value |
| Age, years | | | 0.66 | | | 0.55 | Median | 57 | 58 | | 55 | 60 | | Range | 30–81 | 23–74 | | 30–74 | 24–74 | |
| Gender | | | 0.03 | | | 0.70 | Male | 101 (75.4%) | 34 (91.9%) | | 26 (83.9%) | 28 (90.3%) | | Female | 33 (24.6%) | 3 (8.1%) | | 5 (16.1%) | 3 (9.7%) | |
| ECOG performance score | | | 0.07 | | | 1.00 | 0/1 | 101 (75.4%) | 33 (89.2%) | | 27 (87.1%) | 27 (87.1%) | | 2–4 | 33 (24.6%) | 4 (10.8%) | | 4 (12.9%) | 4 (12.9%) | |
| Primary disease site | | | 0.15 | | | 0.56 | Esophagus | 23 (17.2%) | 12 (32.4%) | | 6 (19.4%) | 10 (32.3%) | | Gastric | 14 (10.5%) | 4 (10.8%) | | 6 (19.4%) | 3 (9.7%) | | Liver | 30 (22.4%) | 9 (24.3%) | | 6 (19.4%) | 6 (19.4%) | | Colorectum | 67 (50.0%) | 12 (32.4%) | | 13 (41.9%) | 12 (38.7%) | |
| Primary histology | | | 0.05 | | | 0.42 | Hepatocellular carcinoma | 27 (20.2%) | 5 (13.5%) | | 4 (12.9%) | 5 (16.1%) | | Squamous cell carcinoma | 15 (11.2%) | 8 (21.6%) | | 4 (12.9%) | 8 (25.8%) | | Adenocarcinoma | 84 (62.7%) | 18 (48.7%) | | 18 (58.1%) | 16 (51.6%) | | Others | 8 (6.0%) | 6 (16.2%) | | 5 (16.1%) | 2 (6.5%) | |
| Radical surgery for primary tumor | | | 0.06 | | | 1.00 | No | 39 (29.1%) | 5 (13.5%) | | 4 (12.9%) | 4 (12.9%) | | Yes | 95 (70.9%) | 32 (86.5%) | | 27 (87.1%) | 27 (87.1%) | |
| Presence of extracranial metastasis | | | <0.01 | | | 1.00 | No | 34 (25.4%) | 18 (48.7%) | | 12 (38.7%) | 12 (38.7%) | | Yes | 100 (74.6%) | 19 (51.4%) | | 19 (61.3%) | 19 (61.3%) | |
| Synchronous or subsequent brain metastasis | | | <0.01 | | | 1.00 | Synchronous | 30 (22.4%) | 1 (2.7%) | | 1 (3.2%) | 1 (3.2%) | | Subsequent | 104 (77.6%) | 36 (97.3%) | | 30 (96.8%) | 30 (96.8%) | |
| Number of brain metastasis | | | 0.20 | | | 0.18 | 1 | 77 (57.5%) | 21 (56.8%) | | 18 (58.1%) | 18 (58.1%) | | 2 | 25 (18.7%) | 7 (18.9%) | | 6 (19.4%) | 5 (16.1%) | | 3 | 4 (3.0%) | 4 (10.8%) | | 0 (0%) | 4 (12.9%) | | ≥4 | 28 (20.9%) | 5 (13.5%) | | 7 (22.6%) | 4 (12.9%) | |
|
|
PSM, propensity score matching; ECOG, Eastern Cooperative Oncology Group.
|